- Home
- EGRX vs RLYB Comparison
EGRX vs RLYB Comparison
Compare EGRX & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGRX
- RLYB
- Stock Information
- Founded
- EGRX 2007
- RLYB 2018
- Country
- EGRX United States
- RLYB United States
- Employees
- EGRX N/A
- RLYB N/A
- Industry
- EGRX Biotechnology: Pharmaceutical Preparations
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- EGRX Health Care
- RLYB Health Care
- Exchange
- EGRX Nasdaq
- RLYB Nasdaq
- Market Cap
- EGRX 50.7M
- RLYB 46.1M
- IPO Year
- EGRX 2014
- RLYB 2021
- Fundamental
- Price
- EGRX $1.99
- RLYB $1.11
- Analyst Decision
- EGRX
- RLYB Buy
- Analyst Count
- EGRX 0
- RLYB 6
- Target Price
- EGRX N/A
- RLYB $8.30
- AVG Volume (30 Days)
- EGRX 321.6K
- RLYB 49.7K
- Earning Date
- EGRX 11-12-2024
- RLYB 11-07-2024
- Dividend Yield
- EGRX N/A
- RLYB N/A
- EPS Growth
- EGRX N/A
- RLYB N/A
- EPS
- EGRX 0.91
- RLYB N/A
- Revenue
- EGRX $257,551,000.00
- RLYB $299,000.00
- Revenue This Year
- EGRX N/A
- RLYB N/A
- Revenue Next Year
- EGRX N/A
- RLYB N/A
- P/E Ratio
- EGRX $2.35
- RLYB N/A
- Revenue Growth
- EGRX N/A
- RLYB N/A
- 52 Week Low
- EGRX $1.80
- RLYB $1.08
- 52 Week High
- EGRX $14.78
- RLYB $4.60
- Technical
- Relative Strength Index (RSI)
- EGRX 19.60
- RLYB 47.41
- Support Level
- EGRX $1.80
- RLYB $1.09
- Resistance Level
- EGRX $4.11
- RLYB $1.18
- Average True Range (ATR)
- EGRX 0.40
- RLYB 0.04
- MACD
- EGRX -0.19
- RLYB 0.00
- Stochastic Oscillator
- EGRX 6.86
- RLYB 22.22
About EGRX Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.